Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: below specification limits for dissolution.
| Brand name | MATZIM LA |
| Generic name | DILTIAZEM HYDROCHLORIDE |
| Active ingredient(s) | DILTIAZEM HYDROCHLORIDE |
| Distributed by / for | Actavis Pharma, Inc., Parsippany, NJ 07054, USA; |
| NDC | 52544-691-30 |
| Full product label | Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30. |
| Recalling firm | Teva Pharmaceuticals USA Inc |
| Distribution | Nationwide in the USA and Puerto Rico |
| Quantity | 8022 bottles |
| Recall initiated | 2022-07-21 |
| Report date | 2022-08-10 |
| Recall completed | 2023-04-18 |
| Recall number | D-1302-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗